Abstract
We evaluated the capacity of the cationic lipid based formulation, Vaxfectin, to enhance the immunogenicity and protective efficacy of DNA-based vaccine regimens in the Plasmodium yoelii murine malaria model. We immunized Balb/c mice with varying doses (0.4-50 microg) of plasmid DNA (pDNA) encoding the P. yoelii circumsporozoite protein (PyCSP), either in a homologous DNA/DNA regimen (D-D) or a heterologous prime-boost DNA-poxvirus regimen (D-V). At the lowest pDNA doses, Vaxfectin substantially enhanced IFA titers, ELISPOT frequencies, and protective efficacy. Clinical trials of pDNA vaccines have often used low pDNA doses based on a per kilogram weight basis. Formulation of pDNA vaccines in Vaxfectin may improve their potency in human clinical trials.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Adjuvants, Immunologic / administration & dosage
-
Animals
-
Antibodies, Protozoan / blood
-
Female
-
Fluorescent Antibody Technique, Indirect
-
Humans
-
Immunization, Secondary
-
Lymphocytes / immunology
-
Malaria / prevention & control*
-
Malaria Vaccines / administration & dosage
-
Malaria Vaccines / genetics
-
Malaria Vaccines / immunology*
-
Mice
-
Mice, Inbred BALB C
-
Phosphatidylethanolamines / administration & dosage
-
Phosphatidylethanolamines / pharmacology*
-
Plasmodium yoelii / immunology*
-
Protozoan Proteins / genetics
-
Protozoan Proteins / immunology*
-
Vaccines, DNA / administration & dosage
-
Vaccines, DNA / genetics
-
Vaccines, DNA / immunology*
-
Vaccinia virus / genetics
Substances
-
Adjuvants, Immunologic
-
Antibodies, Protozoan
-
Malaria Vaccines
-
Phosphatidylethanolamines
-
Protozoan Proteins
-
Vaccines, DNA
-
circumsporozoite protein, Protozoan
-
vaxfectin